NGSHM - Overview: OncoHeme Next-Generation Sequencing (NGS), Hematologic Neoplasms

Test Catalog

Test Name

Test ID: NGSHM    
OncoHeme Next-Generation Sequencing (NGS), Hematologic Neoplasms

Useful For Suggests clinical disorders or settings where the test may be helpful

Evaluation of hematologic neoplasms at the time of diagnosis, to assist in appropriate classification and prognosis

 

Determine the presence of new clinically important gene mutation changes at relapse

Genetics Test Information Provides information that may help with selection of the correct test or proper submission of the test request

This test includes next-generation sequencing to evaluate for the following 35 genes and intronic regions: ASXL1, BCOR, BRAF, CALR, CBL, CEBPA, CSF3R, DNMT3A, ETV6, EZH2, FLT3, GATA1, GATA2, IDH1, IDH2, JAK2, KIT, KRAS, MPL, MYD88, NOTCH1, NPM1, NRAS, PHF6, PTPN11, RUNX1, SETBP1, SF3B1, SRSF2, TERT, TET2, TP53, U2AF1, WT1, and ZRSR2.

Highlights

Next-generation sequencing detection of somatic gene mutations, including type, pattern and distribution, has diagnostic, prognostic, and potential therapeutic implications for patients with hematologic cancers.

 

This test enables more accurate classification of hematologic malignancies.

 

Useful at diagnosis and disease relapse.

Testing Algorithm Delineates situation(s) when tests are added to the initial order. This includes reflex and additional tests.

The following are available in Special Instructions:

-Targeted Genes Interrogated by OncoHeme Next-Generation Sequencing; this is a list of the genes and exons targeted by this test.

-Myelodysplastic Syndrome: Guideline to Diagnosis and Follow-up

Special Instructions and Forms Describes specimen collection and preparation information, test algorithms, and other information pertinent to test. Also includes pertinent information and consent forms to be used when requesting a particular test

Method Name A short description of the method used to perform the test

Somatic Mutation Detection by Next-Generation Sequencing (NGS)

NY State Approved Indicates the status of NY State approval and if the test is orderable for NY State clients.

Yes

Reporting Name A shorter/abbreviated version of the Published Name for a test; an abbreviated test name

OncoHeme NGS for Hematologic Cancer

Aliases Lists additional common names for a test, as an aid in searching

NGS hematologic malignancies
NGS cancer panel, hematologic
Somatic mutation detection by next generation sequencing (NGS), hematologic
Next gen sequencing of leukemia (AML) and myelodysplasia (MDS)
NGS for myeloid neoplasm evaluation (MPN)
Next Gen Sequencing Test
ASXL1
BCOR
BRAF
CALR
CBL
CEBPA
CSF3R
DNMT3A
ETV6
EZH2
FLT3
GATA1
GATA2
IDH1
IDH2
JAK2
KIT
KRAS
MPL
MYD88
NOTCH1
NPM1
NRAS
PHF6
PTPN11
RUNX1
SETBP1
SF3B1
SRSF2
TERT
TET2
TP53
U2AF1
WT1
ZRSR2